Therapy Detail

Therapy Name RNA CART19 cells
Therapy Description

Limited information is currently available on RNA CART19 cells, putative autologous T cells electroporated with RNA expressing CD19 chimeric antigen receptors consists of TCR zeta and 4-1BB costimulatory domains (Aug 2018).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
RNA CART19 cells Limited information is currently available on RNA CART19 cells, putative autologous T cells electroporated with RNA expressing CD19 chimeric antigen receptors consists of TCR zeta and 4-1BB costimulatory domains (Aug 2018).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02624258 Phase I RNA CART19 cells Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma Recruiting